INT262726

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 7
Disease Relevance 7.13
Pain Relevance 0.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (PML) nucleoplasm (PML) endoplasmic reticulum (PML)
intracellular (PML) protein complex assembly (PML) DNA binding (PML)
Anatomy Link Frequency
immune system 1
PML (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 2 99.72 Very High Very High Very High
Multiple sclerosis 64 99.00 Very High Very High Very High
withdrawal 5 86.16 High High
corticosteroid 16 83.96 Quite High
Infliximab 13 73.72 Quite High
Central nervous system 11 66.92 Quite High
imagery 23 30.80 Quite Low
Inflammation 20 5.00 Very Low Very Low Very Low
antagonist 15 5.00 Very Low Very Low Very Low
Demyelination 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 201 100.00 Very High Very High Very High
Progressive Multifocal Leukoencephalopathy 120 100.00 Very High Very High Very High
Leukemia 26 99.82 Very High Very High Very High
Rheumatoid Arthritis 2 99.72 Very High Very High Very High
Infection 29 99.24 Very High Very High Very High
Demyelinating Disease 76 99.00 Very High Very High Very High
Paralysis 3 98.02 Very High Very High Very High
Convulsion 1 97.72 Very High Very High Very High
Ataxia 4 97.52 Very High Very High Very High
Acute Promyelocytic Leukemia 1 97.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Presenting symptoms vary widely, but the most commonly observed are limb weakness, cognitive deficits, speech and visual deficits, incoordination, seizures, and paralysis.12 Unfortunately, other than reconstitution of the immune system, there is currently no effective treatment for PML, and the mortality rate remains as high as 50%.8
Localization (treatment) of PML in immune system associated with progressive multifocal leukoencephalopathy, cognitive disorder, convulsion, ataxia and paralysis
1) Confidence 0.57 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724189 Disease Relevance 1.72 Pain Relevance 0.24
Patients with these leukemias display translocations between the PML (promyelocytic leukemia) gene on chromosome 15 and the RARA (retinoic acid receptor ?)
Localization (translocations) of PML associated with leukemia
2) Confidence 0.52 Published 2009 Journal Nucleic Acids Research Section Body Doc Link PMC2647315 Disease Relevance 1.34 Pain Relevance 0
However PML is an aggressive disease and detection in the asymptomatic stage has rarely if ever been reported presumably because it becomes clinically manifest rapidly, often leading to death within a few months.37
Localization (reported) of PML associated with progressive multifocal leukoencephalopathy, disease and death
3) Confidence 0.35 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789688 Disease Relevance 1.09 Pain Relevance 0.08
A retrospective study conducted by Yousry et al of more than 3000 patients who received natalizumab for multiple sclerosis, Crohn’s disease and rheumatoid arthritis found no new case of PML and suggested a risk of developing the disease is about one per thousand patients (0.2 to 2.8 per thousand) treated with natalizumab for a mean duration of 18 months.32
Localization (case) of PML associated with progressive multifocal leukoencephalopathy, multiple sclerosis, rheumatoid arthritis and disease
4) Confidence 0.35 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789688 Disease Relevance 1.09 Pain Relevance 0.26
Proteins that localize to PML-NBs institute an intrinsic cellular defense against these herpesviruses by silencing viral immediate early (IE) gene expression [84], [85].
Localization (localize) of PML
5) Confidence 0.23 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2936540 Disease Relevance 0.33 Pain Relevance 0
With a known denominator of approximately 3,000 patients who received the drug during clinical trials to treat MS or Crohn’s disease it was possible to estimate a rate of PML in patients who received natazilumab of approximately 1/1,000 (16,17).
Localization (rate) of PML associated with progressive multifocal leukoencephalopathy, multiple sclerosis and disease
6) Confidence 0.21 Published 2008 Journal AAPS J Section Body Doc Link PMC2751449 Disease Relevance 1.17 Pain Relevance 0.15
HHV-5 genomes also co-localize with PML-NBs shortly after infection [83].
Localization (localize) of PML associated with infection
7) Confidence 0.21 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2936540 Disease Relevance 0.39 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox